Pediatric Drug Dosing Reference

GENERAL PEDIATRICS DRUG INFORMATION

Amoxicillin/Clavulanic Acid

Penicillin derivative antibiotic and beta-lactamase inhibitor


Susceptible infections
IV:
Less than 3 months or 4 kg: 25 mg/kg Q12H
3 months or 4 kg or more: 25 mg/kg (usual maximum: 1 g/dose) Q8H
Targeting against Streptococcus pneumoniae (i.e. sequential oral therapy in complicated CAP, AOM, sinusitis)
PO:
80-90 mg/kg/DAY of amoxicillin component (usual maximum: 875mg/dose of amoxicillin. Limit clavulanate to < 10mg/kg/DAY if possible (high risk for diarrhea)) divided Q8-12H
BID dosing may be adequate for AOM, but TID dosing is recommended for pneumonia
Other gram positive, gram negative, anaerobic infections
PO:
30-50 mg/kg/DAY of amoxicillin component (usual maximum: 875mg/dose of amoxicillin. Limit clavulanate to < 10mg/kg/DAY if possible (high risk for diarrhea)) divided Q8-12H
One major side effect with clavulanate (esp at high doses) is GI intolerance.

Availability: Dosed in mg of amoxicillin component.
Tablets (amoxicillin/clavulanate): 250/125 mg (2:1); 500/125 mg(4:1); 875/125 mg(7:1)
Suspension: 80 mg/mL amoxicillin + 11.4 mg/mL clavulanate (7:1).
Please specify ratio (i.e. 7:1) on outpatient prescriptions. Community pharmacies may stock the 4:1 formulation (50 mg/mL amoxicillin and 12.5 mg/mL clavulanate).
Updated: 05/22/2022
Contact Information: This resource is maintained by Mark Duffett (duffett@hhsc.ca), Jon Wong (wongjon@hhsc.ca), and Nicole Clarke (clarken@hhsc.ca)
Disclaimer: This document has been created specifically for Hamilton Health Sciences (HHS) to use for its own patients and the information contained herein may not be applicable or relevant to other health care organizations. This document is for informational purposes only and is not intended to be a substitute for medical or clinical advice from a qualified health care professional. HHS makes no representations or warranties as to the accuracy of the information. This material is current only to the date listed. This material is the intellectual property of HHS and may not be shared, duplicated, or distributed further without the consent of HHS. HHS assumes no liability for the use of this information by the recipient.